Roche Holding AG (OTCMKTS:RHHBY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Roche Holding AG (OTCMKTS:RHHBY) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, three have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $57.00.

A number of equities research analysts have issued reports on RHHBY shares. Citigroup began coverage on shares of Roche in a report on Tuesday, January 27th. They set a “buy” rating for the company. HSBC reissued a “buy” rating and issued a $57.00 price objective on shares of Roche in a research note on Wednesday, December 10th. Morgan Stanley reissued an “underweight” rating on shares of Roche in a research report on Wednesday. Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, The Goldman Sachs Group upgraded shares of Roche from a “sell” rating to a “hold” rating in a report on Thursday, January 15th.

Roche Stock Performance

OTCMKTS RHHBY opened at $57.26 on Thursday. Roche has a 12 month low of $34.75 and a 12 month high of $58.40. The company’s 50 day moving average is $52.29 and its two-hundred day moving average is $45.75. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.29.

Hedge Funds Weigh In On Roche

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Curio Wealth LLC acquired a new position in shares of Roche in the 3rd quarter valued at about $25,000. Oakworth Capital Inc. purchased a new stake in shares of Roche in the third quarter valued at approximately $57,000. First Horizon Advisors Inc. raised its stake in shares of Roche by 81.2% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock worth $75,000 after buying an additional 826 shares during the period. Salomon & Ludwin LLC raised its position in Roche by 256.6% during the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock worth $129,000 after acquiring an additional 2,053 shares during the period. Finally, Albert D Mason Inc. acquired a new position in shares of Roche during the 4th quarter worth about $207,000.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.